Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Femoston vs Duphaston+Divigel vs Klimadynon in Perimenopause
NCT05156814Phase 4Unknown
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of estradiol in perimenopause and hot flashes (3 arms). Primary endpoint: Changes in the average number of hot flashes per day at 84 days. Status: unknown.
02
Drugs
estradiol
03
Conditions
perimenopausehot flashes
Beyond the preview
Go deeper on NCT05156814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156814.